Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia

Files

hdl_139756.pdf (18.01 MB)
  (Published version)

Date

2023

Authors

Kan, W.L.
Dhagat, U.
Hercus, T.R.
Kaufmann, K.B.
Nero, T.L.
Zeng, A.G.X.
Toubia, J.
Barry, E.F.
Broughton, S.E.
Gomez, G.A.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Cancer Discovery, 2023; 13(8):1922-1947

Statement of Responsibility

Winnie L. Kan, Urmi Dhagat, Kerstin B. Kaufmann, Timothy R. Hercus, Tracy L. Nero, Andy G.X. Zeng, John Toubia, Emma F. Barry, Sophie E. Broughton, Guillermo A. Gomez, Brooks A. Benard, Mara Dottore, Karen S. Cheung Tung Shing, Héléna Boutzen, Saumya E. Samaraweera, Kaylene J. Simpson, Liqing Jin, Gregory J. Goodall, C. Glenn Begley, Daniel Thomas, Paul G. Ekert, Denis Tvorogov, Richard J. D, Andrea, John E. Dick, Michael W. Parker, and Angel F. Lopez

Conference Name

Abstract

Leukemia stem cells (LSC) possess distinct self-renewal and arrested differentiation properties that are responsible for disease emergence, therapy failure, and recurrence in acute myeloid leukemia (AML). Despite AML displaying extensive biological and clinical heterogeneity, LSC with high interleukin-3 receptor (IL3R) levels are a constant yet puzzling feature, as this receptor lacks tyrosine kinase activity. Here, we show that the heterodimeric IL3Rα/βc receptor assembles into hexamers and dodecamers through a unique interface in the 3D structure, where high IL3Rα/βc ratios bias hexamer formation. Importantly, receptor stoichiometry is clinically relevant as it varies across the individual cells in the AML hierarchy, in which high IL3Rα/βc ratios in LSCs drive hexamer-mediated stemness programs and poor patient survival, while low ratios mediate differentiation. Our study establishes a new paradigm in which alternative cytokine receptor stoichiometries differentially regulate cell fate, a signaling mechanism that may be generalizable to other transformed cellular hierarchies and of potential therapeutic significance.

School/Discipline

Dissertation Note

Provenance

Description

Published first May 16, 2023 Data source: Supplementary data, https://doi.org/10.1158/2159-8290.CD-22-1396

Access Status

Rights

© 2023 The Authors; Published by the American Association for Cancer Research. This open access article is distributed under the Creative Commons Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

License

Call number

Persistent link to this record